Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Unlike other cancer immunotherapies, the new agent, mezigdomide, can be taken at home as a daily pill.
House Majority Leader Scalise will continue to work while undergoing treatment for multiple myeloma.
The Leukemia & Lymphoma Society funded research leading to a type of targeted immunotherapy called bispecific antibodies.
The new bispecific T-cell engager is approved for people who have received at least four prior lines of treatment.
CU Cancer Center member Saketh Guntupalli, MD, was asked to write an expert review for the British Medical Journal.
Talquetamab is indicated for patients who have tried at least four prior lines of treatment.
A three-drug regimen helps protect against GVHD after stem cell transplant for those with leukemia, lymphoma and similar cancers.
The experimental drug motixafortide helps blood-forming stem cells move from a person’s bone marrow into the bloodstream.
Meet Cameron Ford. At 12, she was diagnosed with multiple myeloma. She’s now 27 and cancer-free. Here, she shares advice for survivors.
Dan Sherbenou, MD, PhD, received an American Cancer Society grant to study resistance to three key treatments for a blood cancer.
New research from Dana-Farber Cancer Institute has identified 116 genes as key molecular vulnerabilities for multiple myeloma.
REGN5459 had decreased binding affinity to T cells, resulting in an encouraging side effect profile and efficacy.
Newly FDA-approved drugs for ovarian, bladder, liver cancer, and more.
Check out these advances in blood cancer research and treatment.
Fred Hutch study suggests certain immune cells are the source of antibodies that attack donated organs.
Immunotherapy leads the way, along with promising breakthroughs for treating leukemia and multiple myeloma.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.